Combating pertussis resurgence: One booster vaccination schedule does not fit all

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 5, 2015, Pages E472-E477

  Riolo, Maria A ^a   Rohani, Pejman ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Booster schedule; Genetic algorithm; Immunization; Pertussis

Indexed keywords

ACELLULAR VACCINE; PERTUSSIS VACCINE;

ALLELE; ARTICLE; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DIAGNOSTIC ERROR; DRUG EFFICACY; GENETIC ALGORITHM; GENOTYPE; HUMAN; IMMUNITY; PERTUSSIS; POINT MUTATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; STOCHASTIC MODEL; SUSCEPTIBLE POPULATION; VACCINATION; VACCINE FAILURE; EPIDEMIC; IMMUNIZATION; IMMUNOLOGY; WHOOPING COUGH;

DISEASE OUTBREAKS; HUMANS; IMMUNIZATION SCHEDULE; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84922327154     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1415573112     Document Type: Article

References (60)

1. Stewart GT (1978) International Symposium on Pertussis, eds Manclark CR, Hill JC (US Department of Health, Bethesda, MD), pp 262-282.
2. Rohani P, Earn DJ, Grenfell BT (1999) Opposite patterns of synchrony in sympatric disease metapopulations. Science 286(5441):968-971.
3. Zhang L, et al. (2010) Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis 16(11):1695-1701.
4. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE; EUVAC-NET Group (2005) Resurgence of pertussis in Europe. Pediatr Infect Dis J 24(9):761-765.
5. Rohani P, Drake JM (2011) The decline and resurgence of pertussis in the US. Epidemics 3(3-4):183-188.
6. Jackson D, Rohani P (2013) The increasing application of multiplex nuclei detection tests to the diagnosis of syndromic infections. Epidemiol Infect 142(1):1-11.
7. Cherry JD (2003) The science and fiction of the "resurgence" of pertussis. Pediatrics 112(2):405-406.
8. Tartof SY, et al. (2013) Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 131(4):e1047-e1052.
9. Mooi FR, van Der Maas NA, De Melker HE (2013) Pertussis resurgence: Waning immunity and pathogen adaptation-Two sides of the coin. Epidemiol Infect 142(4):685-694.
10. Shapiro ED (2012) Acellular vaccines and resurgence of pertussis. JAMA 308(20):2149-2150.
11. Pittet LF, Emonet S, Schrenzel J, Siegrist CA, Posfay-Barbe KM (2014) Bordetella holmesii: An under-recognised Bordetella species. Lancet Infect Dis 14(6):510-519.
12. Riolo MA, King AA, Rohani P (2013) Can vaccine legacy explain the British pertussis resurgence? Vaccine 31(49):5903-5908.
13. Mills KH (2001) Immunity to Bordetella pertussis. Microbes Infect 3(8):655-677.
14. Farizo KM, Burns DL, Finn TM, Gruber MF, Pratt RD (2014) Clinical evaluation of pertussis vaccines: US Food and Drug Administration regulatory considerations. J Infect Dis 209(Suppl 1):S28-S31.
15. Lavine JS, Rohani P (2012) Resolving pertussis immunity and vaccine effectiveness using incidence time series. Expert Rev Vaccines 11(11):1319-1329.
16. Kretzschmar M, Teunis PFM, Pebody RG (2010) Incidence and reproduction numbers of pertussis: Estimates from serological and social contact data in five European countries. PLoS Med 7(6):e1000291.
17. Blackwood JC, Cummings DA, Broutin H, Iamsirithaworn S, Rohani P (2013) Deciphering the impacts of vaccination and immunity on pertussis epidemiology in Thailand. Proc Natl Acad Sci USA 110(23):9595-9600.
18. Jenkinson D (1988) Duration of effectiveness of pertussis vaccine: Evidence from a 10 year community study. Br Med J (Clin Res Ed) 296(6622):612-614.
19. Warfel JM, Zimmerman LI, Merkel TJ (2014) Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 111(2):787-792.
20. Nielsen A, Larsen SO (1994) Epidemiology of pertussis in Denmark: The impact of herd immunity. Int J Epidemiol 23(6):1300-1308.
21. Wearing HJ, Rohani P (2009) Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog 5(10):e1000647.
22. Rohani P, Zhong X, King AA (2010) Contact network structure explains the changing epidemiology of pertussis. Science 330(6006):982-985.
23. Domenech de Celles M, Riolo MA, Magpantay FMG, Rohani P, King AA (2014) Epidemiological evidence for herd immunity induced by acellular pertussis vaccines. Proc Natl Acad Sci USA 111(7):E716-E717.
24. Zepp F, et al. (2011) Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 11(7):557-570.
25. Duclos P, Okwo-Bele J-M, Gacic-Dobo M, Cherian T (2009) Global immunization: Status, progress, challenges and future. BMC Int Health Hum Rights 9(Suppl 1):S2.
26. World Health Organization Department of Immunization, Vaccines, and Biologicals (2013) World Health Organization Vaccine-Preventable Diseases: Monitoring System 2013 Global Summary. Available at apps.who.int/immunization-monitoring/globalsummary/timeseries/tscoveragebcg.htm. Accessed May 19, 2014.
27. Gangarosa EJ, et al. (1998) Impact of anti-vaccine movements on pertussis control: The untold story. Lancet 351(9099):356-361.
28. Omer SB, et al. (2008) Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol 168(12):1389-1396.
29. Imdad A, et al. (2013) Religious exemptions for immunization and risk of pertussis in New York State, 2000-2011. Pediatrics 132(1):37-43.
30. Halperin SA, Bortolussi R, MacLean D, Chisholm N (1989) Persistence of pertussis in an immunized population: Results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 115(5 Pt 1):686-693.
31. Ntezayabo B, De Serres G, Duval B (2003) Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 22(1):22-27.
32. Rohani P, Earn DJ, Grenfell BT (2000) Impact of immunisation on pertussis transmission in England and Wales. Lancet 355(9200):285-286.
33. Halloran ME, Haber M, Longini IM, Jr (1992) Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 136(3):328-343.
34. Halloran ME, Longini IM, Struchiner CJ (2010) Design and Analysis of Vaccine Studies (Springer, Berlin).
35. Preston NW (1965) EFFECTIVENESS OF PERTUSSIS VACCINES. BMJ 2(5452):11-13.
36. Kallonen T, He Q (2009) Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines 8(7):863-875.
37. Hethcote HW (1999) Simulations of pertussis epidemiology in the United States: Effects of adult booster vaccinations. Math Biosci 158(1):47-73.
38. Edmunds WJ, Brisson M, Melegaro A, Gay NJ (2002) The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9-10):1316-1330.
39. de Greeff SC, Mooi FR, Schellekens JFP, de Melker HE (2008) Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 27(3):218-223.
40. Holland JH (1992) Genetic algorithms. Sci Am 267:66-72.
41. World Health Organization Health Statistics and Information Systems (2014) Metrics: Disability-Adjusted Life Year (DALY). Available at www.who.int/healthinfo/global-burden-disease/metrics-daly/en/. Accessed July 23, 2014.
42. Riolo MA, Newman MEJ (2014) First-principles multiway spectral partitioning of graphs. Journal of Complex Networks 2:121-140.
43. McLean AR (1995) Vaccination, evolution and changes in the efficacy of vaccines: A theoretical framework. Proc Biol Sci 261(1362):389-393.
44. Gandon S, Mackinnon MJ, Nee S, Read AF (2001) Imperfect vaccines and the evolution of pathogen virulence. Nature 414(6865):751-756.
45. Knox EG (1980) Strategy for rubella vaccination. Int J Epidemiol 9(1):13-23.
46. Jit M, Choi YH, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337:a769-a769.
47. Medlock J, Galvani AP (2009) Optimizing influenza vaccine distribution. Science 325(5948):1705-1708.
48. de Greeff SC, et al. (2010) Pertussis disease burden in the household: How to protect young infants. Clin Infect Dis 50(10):1339-1345.
49. Mossong J, et al. (2008) Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 5(3):e74.
50. Águas R, Gonc¸alves G, Gomes MGM (2006) Pertussis: Increasing disease as a consequence of reducing transmission. Lancet Infect Dis 6(2):112-117.
51. Lavine JS, King AA, Bjørnstad ON (2011) Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc Natl Acad Sci USA 108(17):7259-7264.
52. Lavine JS, King AA, Andreasen V, Bjørnstad ON (2013) Immune boosting explains regime-shifts in prevaccine-era pertussis dynamics. PLoS ONE 8(8):e72086.
53. Gomes MGM, White LJ, Medley GF (2005) The reinfection threshold. J Theor Biol 236(1):111-113.
54. Clark TA, Messonnier NE, Hadler SC (2012) Pertussis control: Time for something new? Trends Microbiol 20(5):211-213.
55. Anderson RM, May RM (1991) Infectious Diseases of Humans (Oxford Univ Press, Oxford).
56. Keeling MJ, Rohani P (2008) Modeling Infectious Diseases in Humans and Animals (Princeton Univ Press, Princeton).
57. Broutin H, Viboud C, Grenfell BT, Miller MA, Rohani P (2010) Impact of vaccination and birth rate on the epidemiology of pertussis: A comparative study in 64 countries. Proc R Soc Lond B Biol Sci 282(1800):1-7.
58. Goldberg DE, Deb K (1991) A comparative analysis of selection schemes used in genetic algorithms. Urbana 51:69-92.
59. Davidor Y (1990) Epitasis variance: Suitability of a representation to genetic algorithms. Complex Systems 4:369-383.
60. Jones T, Forrest S (1995) Fitness distance correlation as a measure of problem difficulty for genetic algorithms. Proceedings of the Sixth International Conference on Genetic Algorithms, ed Eshelman LJ (Morgan Kaufmann, San Francisco), pp 184-192.